Genentech

#Breaking: Today, we announced our company’s first Direct-to-Patient (DTP) program in an effort to make medicines more affordable to the American people. Just in time for flu season, we are launching a Xofluza® (baloxavir marboxil) initiative to help reduce costs for people who don’t have insurance, have limited coverage or whose health plans don’t cover the medicine. Learn more about how this initiative will support patients and their families. https://lnkd.in/g9uCNH5V Prescribing Information: https://lnkd.in/gJS4fTBx

Building a healthier future for all communities requires bold ideas and collaborative action. As sponsors of this year’s Congressional Hispanic Caucus Institute (CHCI) Leadership Conference and Congressional Black Caucus Foundation Legislative Conference, we connected with policymakers, community leaders and experts on advancing the health and wellbeing of Hispanic, Latino and Black communities. Across the conferences, our leaders sparked dialogue on urgent health issues ranging from equitable AI in healthcare to increasing representation in clinical research and innovating chronic disease care. Our discussions reaffirmed a simple truth: collaboration is key to addressing health disparities and building a more inclusive healthcare system. #CHCIHHM #ALC54

We’re proud to celebrate our principal scientist Jackson Liang, who was selected as a 2025 STAT Wunderkind for his groundbreaking research that is changing how we think about treating estrogen receptor (ER)-positive breast cancer. Congratulations, Jackson! Discover more about how Jackson is contributing to our steadfast pursuit of transformative medicines to improve outcomes for patients with breast cancer. http://spr.ly/6046A0yZ6 #STATWunderkinds

At Genentech, we recognize lupus nephritis as the most serious and potentially life-threatening manifestations of lupus. Delayed diagnosis remains a critical barrier to treatment, even though early intervention is key to preserving kidney function, reinforcing an urgent need for better diagnosis and treatment solutions. That’s why we’re deeply focused on advancing research in lupus nephritis and are working to improve disease understanding, close gaps in care, and ultimately deliver better outcomes for patients. Swipe through to learn the signs and see how our focus on science and innovation is shaping the future of care in lupus nephritis.

#Breaking: At the upcoming European Society for Medical Oncology (#ESMO25) Congress, we’re presenting data across our #oncology portfolio including new research in breast, bladder, lung, and gastrointestinal cancers. These results reflect our unwavering commitment to advancing science where a new therapeutic approach is urgently needed. Explore our latest research: http://spr.ly/6046AxD8o

We're proud to be rooted in South San Francisco. For 33 years, our Genentech Goes to Town program has celebrated and supported the local businesses that are the heart of our community. Since its launch, this program has invested over $4.9 million in more than 300 businesses, with $180,000 supporting nearly 150 small businesses this year alone. This support not only boosts local sales and helps grow customer bases, but also gives our employees the chance to discover new favorite restaurants and deepen their connection to the community. Genentech Goes to Town is a powerful reminder that when we support local, we help build stronger, more resilient communities. Learn more about how we partner with the community year-round: gene.com/ssf

Building a more equitable healthcare system starts with trust. That’s why promotores, trusted community health workers, are essential partners in connecting Hispanic and Latino communities to cancer screenings, boosting health literacy and opening doors to clinical research. We were proud to shine a light on the impact of promotores during #ASCO2025 in Chicago, where we teamed up with The University of Illinois Cancer Center and Café con Conchas for a Spanish‑language dialogue uplifting how localized care and community connection can help break down barriers to better health. Learn more about how we’re collaborating on the ground across the U.S. to improve access to care: http://spr.ly/6046AolVm

We’re excited to share that our very own Aviv Regev, Head of Research and Early Development, has been selected as the 2025 Dickson Prize in Science recipient by Carnegie Mellon University. Aviv has been recognized for her work that pioneered computational methods in single cell and spatial genomics, and for her role as co-founder of the Human Cell Atlas. Congratulations, Aviv!

This year’s National Tribal Health Conference offered powerful insight into what’s ahead for Indigenous health – shaped by sovereignty, driven by culture and sustained through partnership. Thank you, ASU College of Health Solutions and National Indian Health Board for welcoming us into this meaningful space and spotlighting how the community-driven programs supported by our Innovation Fund are transforming health outcomes for Indigenous communities. We look forward to continuing to work alongside Tribal leaders and partners in this vital work. Learn more about ASU's work to advance healthcare access and outcomes for Indigenous communities here: http://spr.ly/6049AcvWP Pictured: Photo 1: Dr. John Molina, Director of the Arizona Advisory Council on Indian Health Care, greets a guest at the National Indian Health Board’s Gala – “Voices of Our Tribes” Photo 2: ASU colleagues, alumni, and community leaders gather to celebrate at the National Indian Health Board’s Gala – “Voices of Our Tribes” Photo 3: Dr. Angela Gonzales, Director & Professor of American Indian Studies, presents on ASU’s Indigenous Health Initiative at the National Indian Health Board’s 2025 National Tribal Health Conference

The FDA approved our new treatment regimen for extensive-stage small cell #LungCancer (ES-SCLC). Learn more about the first and only combination therapy approved for first-line maintenance treatment of ES-SCLC, an aggressive and difficult to treat form of lung cancer: http://spr.ly/6047AcfbR